19:38 , Apr 27, 2018 |  BC Week In Review  |  Company News

Tonghua gets rights to two insulin products from Adocia

Adocia S.A. (Euronext:ADOC) granted Tonghua Dongbao Pharmaceutical Co. Ltd. (Shanghai:600867) exclusive rights to develop and commercialize BioChaperone Lispro (BioChaperone Ultra fast-acting insulin analog) and BioChaperone insulin combo in China and other undisclosed countries. Adocia will receive...
23:10 , Aug 1, 2017 |  BC Extra  |  Company News

Management tracks: Bicycle, ReNetX, ALK-Abello

Peptide company Bicycle Therapeutics Ltd. (Cambridge, U.K.) named Lee Kalowski CFO. He was CFO of Tokai Pharmaceuticals Inc., which merged with Otic Pharma Ltd. to form Novus Therapeutics Inc. (NASDAQ:NVUS). Neurology play ReNetX Bio (New Haven,...
06:12 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

Adocia begins head-to-head trial of BioChaperone Lispro vs. Fiasp and Novolog

In early June, Adocia S.A. (Euronext:ADOC) began a 3-way crossover Phase II trial to compare single subcutaneous doses of 0.15 U/kg BioChaperone Lispro vs. 0.15 U/kg Fiasp (faster-acting insulin aspart, NN1218) or 0.15 U/kg Novolog...
19:53 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Adocia starts Phase I trial of BioChaperone glucagon to treat Type I diabetes

Adocia S.A. (Euronext:ADOC) began a Phase I trial to compare 2 formulations of subcutaneous BioChaperone glucagon to GlucaGen HypoKit from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) in about 27 patients with Type I diabetes. Patients will...
00:41 , Feb 3, 2017 |  BC Week In Review  |  Company News

Adocia, Lilly deal

Eli Lilly terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type I and Type II diabetes. Lilly had paid $50 million up front for exclusive, worldwide rights to the ultra-fast-acting...
23:13 , Jan 27, 2017 |  BC Extra  |  Company News

Lilly returns diabetes candidate to Adocia

Adocia S.A. (Euronext:ADOC) sank EUR 12.67 (31%) to EUR 27.60 after it said Eli Lilly and Co. (NYSE:LLY) terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type I and Type...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase Ib started

Adocia began a double-blind, double-dummy, 3-way crossover, German Phase Ib trial of subcutaneous BioChaperone Combo given before a meal on 3 consecutive days in 36 patients. The trial will compare BioChaperone Combo vs. subcutaneous ...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

BioChaperone PDGF-BB: Development halted

Adocia said it will halt development of BioChaperone PDGF-BB to treat diabetic foot ulcers after top-line data from a double-blind, Indian Phase III trial in 252 patients showed that 4 ug/cm 2 BioChaperone PDGF-BB spray...
07:00 , Aug 26, 2016 |  BC Extra  |  Clinical News

Adocia halting diabetic foot ulcer programs after Phase III miss

Adocia S.A. (Euronext:ADOC) said its BioChaperone PDGF-BB spray missed the primary endpoint in an Indian Phase III study to treat diabetic foot ulcers. The candidate did not significantly improve complete wound closure after 20 weeks...